Viking Therapeutics (VKTX) Other Accumulated Expenses (2016 - 2025)
Historic Other Accumulated Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $21.2 million.
- Viking Therapeutics' Other Accumulated Expenses fell 1496.53% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 1496.53%. This contributed to the annual value of $17.1 million for FY2024, which is 5143.82% up from last year.
- Per Viking Therapeutics' latest filing, its Other Accumulated Expenses stood at $21.2 million for Q3 2025, which was down 1496.53% from $26.0 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Other Accumulated Expenses ranged from a high of $27.2 million in Q1 2024 and a low of $7.3 million during Q4 2021
- Over the past 5 years, Viking Therapeutics' median Other Accumulated Expenses value was $11.3 million (recorded in 2023), while the average stood at $13.2 million.
- As far as peak fluctuations go, Viking Therapeutics' Other Accumulated Expenses surged by 23831.86% in 2024, and later plummeted by 5821.82% in 2025.
- Over the past 5 years, Viking Therapeutics' Other Accumulated Expenses (Quarter) stood at $7.3 million in 2021, then surged by 79.52% to $13.1 million in 2022, then fell by 13.84% to $11.3 million in 2023, then surged by 51.44% to $17.1 million in 2024, then increased by 24.0% to $21.2 million in 2025.
- Its last three reported values are $21.2 million in Q3 2025, $26.0 million for Q2 2025, and $11.4 million during Q1 2025.